NCT07594093RecruitingPhase 1
Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of REGN20934 in Adult Participants With Overweight or Obesity
Source: ClinicalTrials.gov · Last updated 25 Sept 2026
Brief summary (registry, in English)
This study will test a study drug called REGN20934 to see how safe and well tolerated this drug is, as well as how the drug is processed in the body for participants with overweight or obesity. The study is looking at: * What side effects REGN20934 might cause * How much REGN20934 is in the blood at different times * If the body makes antibodies to REGN20934
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- First submitted
- 11 May 2026
- Start date
- 29 Jun 2026
- Primary completion date
- 22 Feb 2027
- Lead sponsor
- Regeneron Pharmaceuticals
- Diseases
- Obesity
- NCT number
- NCT07594093
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 90
- From 29 Jun 2026 to the primary completion date, 22 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of type 1 or type 2 diabetes
- History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disease, as defined in the protocol
- Note: Other protocol defined inclusion/exclusion criteria apply
Other
- A self-reported change of body weight \>5 kg within approximately 90 days of visit 2
Who the study is looking for
- Has a Body Mass Index (BMI) 25 to 35 kg/m\^2
- Females must be of non-childbearing potential
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Parexel International Coordinator of this site? Confirm its status | Glendale | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.